临床试验/NCT04571372

NCT04571372已完成不适用

Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

Yonsei University2 个研究点分布在 2 个国家目标入组 222 人开始时间: 2020年8月14日最近更新: 2026年7月13日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Yonsei University
入组人数: 222
试验地点: 2
主要终点: Number of participants with adverse clinical outcomes

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 19 Years 至 99 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age ≥ 19 yrs
•Severe aortic stenosis or severe aortic regurgitation
•Agree to consent for self
•Can follow-up for the next 2 years

排除标准

•Pre-existing acute kidney injury
•Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15 ml/min/1.73m2 or receiving renal replacement therapy
•On ECMO or IABP
•Life expectancy < 12 months
•Pregnancy

研究组 & 干预措施

Patients with severe aortic stenosis or severe aortic regurgitation

结局指标

主要结局

Number of participants with adverse clinical outcomes

时间窗: 2 years after recruiting

Composite of all-cause death, cardiovascular mortality, and worsening of kidney function

Number of participants with adverse clinical outcomes

时间窗: Immediate post operation

Composite of all-cause death, cardiovascular mortality, and worsening of kidney function

次要结局

未报告次要终点

研究者

发起方

Yonsei University

申办方类型

Other

责任方

Sponsor

研究点 (2)

Loading locations...

相似试验

已完成

不适用

Prognostic Value of Soluble Urokinase Plasminogen Activation Receptor (SUPAR) to Rule Out Complications in Patients Admitted in Emergency Department for Acute Abdominal Pain.Soluble Urokinase Plasminogen Activation ReceptorAbdominal PainEmergency DepartmentMortality

NCT05580016Poitiers University Hospital200

已完成

不适用

SuPAR in Adult Patients With Covid-19Covid19

NCT04590794University of Thessaly767

已完成

不适用

Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE)Surgery--Complications

NCT03851965University of Thessaly100

已完成

不适用

Role of suPAR in Periodontitis and CVDMetabolic DisturbancePeriodontal Diseases

NCT04335344University of Messina326

已完成

不适用

Predictive Value of suPAR and hsCRP on Postoperative Mortality in Cardiac SurgeryThoracic SurgeryCardiac Surgical ProceduresBiomarkers

NCT04292249Rigshospitalet, Denmark951